Gillmore J D, Davies J, Iqbal A, Madhoo S, Russell N H, Hawkins P N
Division of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London.
Br J Haematol. 1998 Jan;100(1):226-8. doi: 10.1046/j.1365-2141.1998.00527.x.
Low-intensity chemotherapy is ineffective in most patients with AL amyloidosis, probably because clinical benefit requires regression of the amyloid deposits, and this occurs only very gradually after the underlying plasma cell dyscrasia has been suppressed. We report the first successful allogeneic bone marrow transplant (allo-BMT) for AL amyloidosis, which after 3 years was associated with complete clinical recovery. This supports the idea that there may be a brief window of opportunity in patients with AL amyloidosis during which dose-intensive chemotherapy is feasible and most likely to produce clinical benefit.
低强度化疗对大多数 AL 淀粉样变性患者无效，可能是因为临床获益需要淀粉样沉积物消退，而这只有在潜在的浆细胞发育异常被抑制后才会非常缓慢地发生。我们报告了首例成功的用于 AL 淀粉样变性的异基因骨髓移植（allo-BMT），3 年后患者实现了完全临床康复。这支持了这样一种观点，即 AL 淀粉样变性患者可能存在一个短暂的机会窗口，在此期间进行剂量密集化疗是可行的，并且最有可能产生临床获益。
